Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-04
2007-12-04
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S383000, C514S364000, C514S378000, C514S314000, C514S340000, C548S263200, C548S131000, C548S249000, C544S132000, C546S272400, C546S174000
Reexamination Certificate
active
10415673
ABSTRACT:
The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C1-C8alkyl, aryl-C0-2-alkyl, heteroaryl-C0-2-alkyl, C3-C6cycloalkylaryl-C0-2-alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C1-C6alkyl, C3-C6cycloalkyl and heteroaryl. X is a C2-C5alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH2)nCOOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C1-C5alkyl, C1-C5alkoxy. Additionally, R4 is H, halo, a substituted or unsubstituted group selected from C1-C5alkyl, C1-C5alkoxy, C3-C6cycloalkyl, arylC0-C4alkyl and phenyl, or R3 and R4 are combined to form a C3-C4cycloalkyl.
REFERENCES:
patent: 5536736 (1996-07-01), Hamanaka et al.
patent: 5641796 (1997-06-01), Dominianni et al.
patent: 5817677 (1998-10-01), Linz et al.
patent: 1028111 (2000-08-01), None
patent: WO96/13264 (1996-05-01), None
patent: WO96/35680 (1996-11-01), None
patent: WO99/08501 (1999-02-01), None
patent: WO 01/00603 (2001-01-01), None
patent: WO 01/40207 (2001-06-01), None
patent: WO 02/083128 (2002-10-01), None
Database CAS ONLINE on STN, Chem. Abstr., Accession No. 1966:473439, Kurzer et al., Chemistry & Industry, (1966), (26), 1143 (abstract only).
Database CAS ONLINE on STN, Chem. Abstr., Accession No. 1943: 16721, Girard, Compt. rend. (1941), 212, 547-9, (abstract only).
Database CAS ONLINE on STN, Chem. Abstr., Accession No. 1913:5473, Fromm, Ann. (1913), 394, 258-84, (abstract only).
Database CAS ONLINE on STN, Chem. Abstr., Accession No. 1962:423199, Bellioni, Annali di Chimica, (1962), 52, 187-91, (abstract only).
Brittain “polymorphism in pharmaceutical solids” marcel Dekker, p. 1, 2, 178-179, 185, 219 and 236 (1999).
US Pharmacopia #23, national formulary #18, p. 1843-1844 (1995).
Haluzik et al., Physiol. Res. 55: 115-122, 2006.
Nissen et al., JAMA, Nov. 23/30, 2005, vol. 294, No. 20, pp. 2582-2586.
McMahonn et al., Diabetes Care, vol. 28, No. 5, May 2005, pp. 1145-1150.
Allred et al., Molucular and Cellular Endocrinology 235 (2005) 21-29.
Science (1999), vol. 286, 531-537.
Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Wilson, T.M., et al., “The Structure—Activity Relationship Between Peroxisome Proliferator-Activated Receptor γ Agonism and the Antihyperglycemic Activity of Thiazolidinediones,” J. Med. Chem., vol. 39, 665-668, 1996.
Dominianni Samuel James
Etgen Garret Jay
Johnston Richard Duane
Mantlo Nathan Bryan
Mayhugh Daniel Ray
Anderson Rebecca
Eli Lilly and Company
Vorndran-Jones MaCharri
LandOfFree
Peroxisome proliferator activated receptor alpha agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peroxisome proliferator activated receptor alpha agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peroxisome proliferator activated receptor alpha agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3828591